Big pharma, Deals

Collaboration agreement for oncology drug candidates targeting apoptosis regulation pathways

Posted on 13 May 2014

Tags: , ,

Servier have signed a strategic global collaboration agreement with Novartis to develop and commercialize a series of novel drugs candidates issued from the Servier research programs partnered with Vernalis in oncology which are targeting the apoptosis regulation pathways.

The collaboration covers the worldwide co-development of BCL-2 selective inhibitor candidates that are now entering into clinical development.

Proteins of the BCL-2 family are crucial regulators of apoptosis.

Deregulations of this protein family play a major role in the aberrant survival of tumor cells.

Servier will remain responsible for research activities and will share responsibilities with Novartis to conduct a clinical development program aimed at moving swiftly to a first indication for the benefit of patients.

Commercialization rights to products arising from the collaboration will be allocated between the parties on a geographic basis.

For further deal information visit Current Agreements (subscription required)

Related

Read: Novartis Company Profile

Report: Partnering Deals and Alliances with Novartis

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply